Antibody Engineering Xchange EAST COAST 2018

Antibody Engineering

Time

Titles and Bullets

Facilitator

9:00am – 10:00am

How to identify which is the best antibody platform to move forward with for lead identification?

What should be the most important selection criteria?
Deciding factors to weigh risk and value
Technology evolution, why and how?
What does the trajectory predict for the future?

Partha Chowdhury

Senior Director & Head
Antibody Discovery
Sanofi

10:30am – 11:30am

Selection of antibodies specific for multi-pass membrane proteins using mammalian virus display.

What are the biggest challenges to overcome to enable selection of antibodies specific for multi-pass membrane proteins?
What are the available technical solutions to these challenges?
How can recombinant virus display and VLPs be used to overcome these challenges?

Ernest Smith

Senior Vice President
Research & Chief Scientific Officer
Vaccinex

12:00pm – 13:00pm

How to validate conformation-specific antigen targets?

How do we know the selected antibodies bind a specific conformation such as a disease-specific form?
How can we differentiate normal and disease-related forms?
What methods can be used to validate protein conformations?

Michael Sierks

Professor
Chemical Engineering
Arizona State University

3:15pm – 4:15pm

Applications of antibody decoding through protein sequencing.

Applications of protein sequencing- is DNA sequencing the only choice?
Issues in antibody reproducibility and solutions. Is your mAb truly monoclonal?
Advances in MS sequencing; does Ile/Leu differentiation matter?
Future directions: MS sequencing in recombinant polyclonal antibodies.

Anthony Stajduhar

Manager
Sales & Business Development
Rapid Novor

4:20pm – 5:20pm

How to apply NGS technology to speedup Ab lead discovery and increase lead Ab sequence diversity

Can NGS help your Ab discovery effort?
NGS platform: MiSeq or HiSeq, which one is more suitable for Ab library sequencing?
Sequencing Data analysis
How to pick Ab hits from NGS sequencing results?

Zhinan Xia

Senior Director
Henlix

Antibody Engineering

Time

Titles and Bullets

Facilitator

9:00am – 10:00am

Antibody optimization strategies balancing antigen affinity, functional activity, and manufacturing developability.

Approaches to antigen affinity optimization – structure-based rational design vs high throughput screening vs phage display
Optimization of effector function and multi-specificity subsequent or in parallel to affinity maturation
When and how to assess developability potential of lead candidates

Clark Pan

Vice President
Head of Discovery Therapeutics
Shire

10:30am – 11:30am

A balanced approach to developability analysis throughout antibody discovery

How early do we begin our developability assessments during the drug discovery process?
How do we prioritise antibody attributes at each stage of the process?
Which analytical approaches are most valuable in initial developability assessments?

Hugh Morgan

Senior Scientist & Team Leader
Antibody Purification and Analytics
Fusion Antibodies

12:00pm – 1:00pm

Antibody Fc engineering for PK and effector function modulation

How low is low enough for antibody’s effector function when a silent Fc format is needed?
What are the benefits of engineering for antibody that specifically binds to one type of FcγR?
What other factors contribute to antibody PK beside FcRn binding?
What are the major issues of the existing Fc formats?

Huawei Qiu

Senior Director, Head of Protein Engineering
Sanofi Genzymex

3:15pm – 4:15pm

Overcoming design and evaluation challenges of next-generation cancer immunotherapies.

How to choose an appropriate antibody modality? Bispecific, ADC, CAR-T, fragment, monotherapy, combinations
The relevance/translation of animal models, transgenics, surrogates
How to choose and evaluate antibody subclass?

Yasmina Abdiche

Chief Scientific Officer
Carterra

4:20pm – 5:20pm

New frontiers in precision medicine: Using patient’s own cells as an antibody production system for treatment of cancer

Approaches to personalized antibody product
Translating from animal models to practical impacts in patients
Challenges of in-vivo antibodies half-life in different areas of the body, e.g., brain
Overcoming anti-drug antibodies

Inbal Zafir-Lavie

Senior Scientist, Translational Medicine
Aevi Genomic Medicine

Bispecific Antibodies

Time

Titles and Bullets

Facilitator

9:00am – 10:00am

Implementing strategies to enhance bispecific activity

Current limitations of bispecifics for the treatment of solid tumor indications

a) On-target, off-tumor DLTs in the clinic

b) Lack of clean tumor targets for solid tumors

Strategies to overcome current limitations of bispecifics for solid tumor targeting

a) Key differentiation between platforms

b) Technology and biology update

Hans-Peter Gerber

President & Chief Scientific Officer
Maverick Therapeutics

12:00pm – 1:00pm

Bispecifics and CARs: Different challenges for anti-cancer vs. anti-HIV applications

Duration of function
Location, location, location
Anti-drug antibodies

Edward Berger

Chief, Molecular Structure Section
LVD, NIAID
National Institutes of Health

4:20pm – 5:20pm

Developing a plug-and-play platform approach for bispecific generation and development

Optimal building blocks for bispecific engineering
Impact of bispecific formats on pharmacological activities
Impact of bispecific formats on developability

Chung-Ming Hsieh

Executive Director
Biologics Discovery
Merck

Antibody Drug Conjugates

Time

Titles and Bullets

Facilitator

9:00am – 10:00am

Developing next-generation ADCs to improve therapeutic index

Engineering homogeneous and stable ADCs – are we there yet to address the therapeutic Index of ADC?
How to address the on-target toxicities associated with ADCs?
How to address the off-target toxicities often observed in ADCs?
How to optimize the linker and warhead for preferred killing of tumor cells?

Changshou Gao

Senior Director & Fellow
R&D
MedImmune

10:30am – 11:30am

Linker-payload technologies: Where should the focus be to deliver improvements?

Site specific conjugation chemistries?
Payloads and attachment chemistry?
Linkers?

Rory Curtis

Vice President Discovery Biology & Pharmacology & Site Head
AMRI

12:00pm – 1:00pm

Translating ADCs from preclinical into clinical

How can we use data from the clinical studies to improve the preclinical development of ADCs?
How has ADC technology improved and what are the shortcomings?
Will improvements in the preclinical development of ADCs improve the clinical success rates for ADCs?

3:15pm – 4:15pm

Antibody drug conjugates and mechanisms of resistance

Does the unique structure and function of antibody-drug conjugates (ADCs) suggest specific mechanisms of primary resistance?
How might some of the ADC components be modified to overcome these mechanisms of resistance?

James Huebner

Principal
Pharminteg LLC

4:20pm – 5:20pm

Hidden in plain sight: Secrets to building successful ADCs

How do we design & interpret preclinical studies to be predictive of the clinic?
How can we be more efficient: which assays matter, and which don’t?
Which technologies are most promising for next-generation ADCs?
Where is the greatest clinical opportunity for ADCs?

Marc Damelin

Senior Director
Head of Biology
Mersana Therapeutics

Cancer Immunotherapies

Time

Titles and Bullets

Facilitator

9:00am – 10:00am

Designing multispecific antibody-based biotherapeutics for optimal anti-tumour responses

What is needed to make informed choices about target selection?
Platform modalities: does one size fit all?
Limits of biology: biophysical properties of a drug vs target expression
Is it all about T cells?

Theresa Goletz

Global Head
NBE Drug Disposition
EMD Serono

12:00pm – 1:00pm

How to differentiate and stand out in a very competitive and crowded space

How to overcome the limitations for the identification of novel targets
Have the most relevant I/O targets already been exploited, which one will be the next frontier?
Impact of Ab format on MOA and efficacy
Will the future be dominated by single agents or combinations?

Horacio Nastri

Senior Director
Antibody Biotherapeutics,
Incyte Corporation

3:15pm – 4:15pm

ANTIBODY DISCOVERY TOPIC How to effectively use Rabbit monoclonal antibodies for therapeutic antibody discovery?

Rabbit monoclonal antibodies as an antibody tool for therapeutic antibody discovery
Which technique is better: B cell cloning or phage display?
How to achieve high reproducibility of antibodies?

Li Hui

Principal Scientist, Rabbit Monoclonal Antibody Discovery
ABclonal

4:20pm – 5:20pm

Developing bispecific antibodies for immuno-oncology.

Why a bispecific versus a combination of two antibodies?
What valency of binding to each target is optimal for the desired mechanism of action?
How do you select the optimal antibody specificities to function in context of a bispecific?

Paul Moore

Vice President
Research
MacroGenics

Antibody Engineering Xchange EAST COAST 2018

Antibody Engineering

Antibody Engineering

Bispecific Antibodies

Antibody Drug Conjugates

Cancer Immunotherapies

Partners

Do you want a free sketch for your homepage? Visit Weblify.se